Linked Life Data

16797163

Source:http://linkedlifedata.com/resource/pubmed/id/16797163

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-3
pubmed:dateCreated
2006-7-3
pubmed:abstractText
Cognitive impairment has the greatest impact on illness outcome in schizophrenia. The most significant challenge in schizophrenia therapeutics, thus, is to develop an efficacious treatment for cognitive impairments. Acetylcholinesterase inhibitors, such as Physostigmine and Rivastigmine, are considered effective treatments for cognitive decline in Alzheimer's Disease, where the loss of cholinergic neurons is thought to be responsible for various cognitive deficits. The current study investigated the cognitive effects of Rivastigmine given as an add-on therapy to antipsychotic-treated schizophrenia patients in a placebo-controlled double-blind design. The study initially involved 40 patients, of which 21 patients (11 assigned to Rivastigmine and 10 assigned to placebo) agreed to continued participation, remained on the study drug, and underwent assessment of executive functioning, verbal skills, verbal and spatial working memory, attention and psychomotor speed on three occasions: (i) at baseline, and then (ii) after 12 weeks and (iii) 24 weeks of treatment with placebo or Rivastigmine. The results failed to reveal significant improvement on any cognitive measure with Rivastigmine treatment, compared with the placebo treatment. Some cognitive variables showed significant practice effects in both the placebo and Rivastigmine groups. No effects were noted in symptoms or side effects ratings. The beneficial cognitive effects of Rivastigmine seen in an open-label preliminary study are not substantiated by this study. Future studies should investigate the effects of other procholinergic drugs, such as Galantamine, which also act on the nicotine receptors and may produce stronger cognitive effects in schizophrenia.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0920-9964
pubmed:author
pubmed:issnType
Print
pubmed:volume
85
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
73-83
pubmed:dateRevised
2010-9-2
pubmed:meshHeading
pubmed-meshheading:16797163-Adult, pubmed-meshheading:16797163-Antipsychotic Agents, pubmed-meshheading:16797163-Cholinesterase Inhibitors, pubmed-meshheading:16797163-Cognition Disorders, pubmed-meshheading:16797163-Double-Blind Method, pubmed-meshheading:16797163-Female, pubmed-meshheading:16797163-Ganglionic Stimulants, pubmed-meshheading:16797163-Humans, pubmed-meshheading:16797163-Male, pubmed-meshheading:16797163-Middle Aged, pubmed-meshheading:16797163-Neuropsychological Tests, pubmed-meshheading:16797163-Nicotine, pubmed-meshheading:16797163-Phenylcarbamates, pubmed-meshheading:16797163-Physostigmine, pubmed-meshheading:16797163-Psychomotor Performance, pubmed-meshheading:16797163-Schizophrenia, pubmed-meshheading:16797163-Severity of Illness Index, pubmed-meshheading:16797163-Verbal Behavior
pubmed:year
2006
pubmed:articleTitle
Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
pubmed:affiliation
Clinical Research, Clinical Neuroscience Research Centre, Priory Hill, Dartford, Kent, UK. t.sharma@psychmed.org.uk
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't